NZ710575A - Pharmaceutical compositions for the treatment of diabetes mellitus - Google Patents

Pharmaceutical compositions for the treatment of diabetes mellitus

Info

Publication number
NZ710575A
NZ710575A NZ710575A NZ71057510A NZ710575A NZ 710575 A NZ710575 A NZ 710575A NZ 710575 A NZ710575 A NZ 710575A NZ 71057510 A NZ71057510 A NZ 71057510A NZ 710575 A NZ710575 A NZ 710575A
Authority
NZ
New Zealand
Prior art keywords
diabetes mellitus
treatment
prevention
pharmaceutical compositions
disclosed
Prior art date
Application number
NZ710575A
Other languages
English (en)
Inventor
Saeko Uchida
Teisuke Takahashi
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of NZ710575A publication Critical patent/NZ710575A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ710575A 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus NZ710575A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
NZ623838A NZ623838A (en) 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
NZ710575A true NZ710575A (en) 2016-06-24

Family

ID=42982643

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ606888A NZ606888A (en) 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus
NZ710575A NZ710575A (en) 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus
NZ595314A NZ595314A (en) 2009-04-16 2010-04-16 PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
NZ623838A NZ623838A (en) 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ606888A NZ606888A (en) 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ595314A NZ595314A (en) 2009-04-16 2010-04-16 PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
NZ623838A NZ623838A (en) 2009-04-16 2010-04-16 Pharmaceutical compositions for the treatment of diabetes mellitus

Country Status (30)

Country Link
US (1) US20120040898A1 (enExample)
EP (3) EP2419097B1 (enExample)
JP (4) JP5077786B2 (enExample)
KR (2) KR20120016051A (enExample)
CN (7) CN105343060A (enExample)
AR (1) AR076317A1 (enExample)
AU (1) AU2010237748B2 (enExample)
BR (1) BRPI1012539A2 (enExample)
CA (1) CA2755392A1 (enExample)
CY (2) CY1114703T1 (enExample)
DK (2) DK2601949T3 (enExample)
ES (2) ES2523408T3 (enExample)
HK (6) HK1217301A1 (enExample)
HR (2) HRP20131120T1 (enExample)
ME (2) ME02015B (enExample)
MX (1) MX2011010901A (enExample)
MY (3) MY182720A (enExample)
NZ (4) NZ606888A (enExample)
PH (3) PH12015500235B1 (enExample)
PL (2) PL2601949T3 (enExample)
PT (2) PT2601949E (enExample)
RS (2) RS53761B1 (enExample)
RU (2) RU2532330C2 (enExample)
SG (6) SG2014014807A (enExample)
SI (2) SI2601949T1 (enExample)
SM (1) SMT201500015B (enExample)
TW (3) TW201103534A (enExample)
UA (2) UA105216C2 (enExample)
WO (1) WO2010119990A1 (enExample)
ZA (1) ZA201106727B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2878001T3 (es) 2012-05-17 2021-11-18 Vtv Therapeutics Llc Composiciones del activador de la glucocinasa para el tratamiento de la diabetes
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
JP6467583B2 (ja) * 2015-02-27 2019-02-13 ジ アサン ファウンデーション Ｄｐｐ−４の抑制剤を含む弁膜石灰化の予防または治療用の組成物
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
JP7625363B2 (ja) 2016-11-10 2025-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
JP7066209B2 (ja) * 2016-11-14 2022-05-13 高雄醫學大學 糖代謝異常の検出方法と予防及び治療
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
MY206745A (en) 2018-10-29 2025-01-04 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
EP2065044A1 (en) 2001-04-04 2009-06-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
CA2444481A1 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CN101479254B (zh) * 2006-06-29 2012-05-30 大正制药株式会社 C-苯基1-硫代山梨醇化合物
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
CL2007003227A1 (es) * 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
RU2009126767A (ru) * 2006-12-14 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. (Jp) Производное 1-фенил-1-тио-d-глюцитола
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv

Also Published As

Publication number Publication date
BRPI1012539A2 (pt) 2016-03-29
KR20150046382A (ko) 2015-04-29
EP2601949A3 (en) 2013-09-18
TW201622720A (zh) 2016-07-01
HK1218881A1 (zh) 2017-03-17
JP5910711B2 (ja) 2016-04-27
SG2014012405A (en) 2014-05-29
PH12019500959A1 (en) 2020-06-29
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
EP2419097A1 (en) 2012-02-22
AR076317A1 (es) 2011-06-01
PL2419097T3 (pl) 2014-02-28
MY182720A (en) 2021-02-03
UA111742C2 (uk) 2016-06-10
RU2014121260A (ru) 2015-12-10
ME01555B (me) 2014-04-20
CN105477639A (zh) 2016-04-13
MY183793A (en) 2021-03-16
SG2014015093A (en) 2014-04-28
AU2010237748B2 (en) 2014-10-30
NZ595314A (en) 2013-03-28
RS53056B (sr) 2014-04-30
MX2011010901A (es) 2011-11-01
CY1115907T1 (el) 2017-01-25
DK2601949T3 (da) 2015-01-05
CN102395364A (zh) 2012-03-28
CN105343880A (zh) 2016-02-24
RU2532330C2 (ru) 2014-11-10
HRP20131120T1 (hr) 2013-12-20
JP2016104775A (ja) 2016-06-09
RU2011146335A (ru) 2013-05-27
JP2015063543A (ja) 2015-04-09
HK1217434A1 (zh) 2017-01-13
JP5077786B2 (ja) 2012-11-21
EP2419097A4 (en) 2012-09-05
CA2755392A1 (en) 2010-10-21
HK1218871A1 (zh) 2017-03-17
CY1114703T1 (el) 2016-10-05
PH12019500961A1 (en) 2020-08-03
CN105434430A (zh) 2016-03-30
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
JP2012524710A (ja) 2012-10-18
SG2014012553A (en) 2014-05-29
EP2419097B1 (en) 2013-09-25
EP2601949A2 (en) 2013-06-12
ES2523408T3 (es) 2014-11-25
JP2013006854A (ja) 2013-01-10
PH12015500235A1 (en) 2015-12-02
SG2014012462A (en) 2014-05-29
UA105216C2 (en) 2014-04-25
WO2010119990A1 (en) 2010-10-21
NZ606888A (en) 2014-07-25
PL2601949T3 (pl) 2015-04-30
CN105343060A (zh) 2016-02-24
JP5660094B2 (ja) 2015-01-28
PT2601949E (pt) 2014-11-12
TW201500043A (zh) 2015-01-01
SG2014014807A (en) 2014-05-29
DK2419097T3 (da) 2013-10-28
NZ623838A (en) 2015-09-25
RS53761B1 (sr) 2015-06-30
CN105343059A (zh) 2016-02-24
JP6066144B2 (ja) 2017-01-25
HK1217435A1 (zh) 2017-01-13
PH12015500235B1 (en) 2015-12-02
EP2829271A3 (en) 2015-05-27
EP2601949B1 (en) 2014-10-29
MY156679A (en) 2016-03-15
TW201103534A (en) 2011-02-01
US20120040898A1 (en) 2012-02-16
SMT201500015B (it) 2015-03-05
SG175154A1 (en) 2011-11-28
SI2601949T1 (sl) 2014-12-31
PH12019500959B1 (en) 2020-06-29
PT2419097E (pt) 2013-10-03
PH12019500961B1 (en) 2020-08-03
CN105343871A (zh) 2016-02-24
ES2431300T3 (es) 2013-11-25
HK1217302A1 (zh) 2017-01-06
ME02015B (me) 2015-05-20
ZA201106727B (en) 2012-11-28
AU2010237748A1 (en) 2011-10-20
HK1217301A1 (zh) 2017-01-06

Similar Documents

Publication Publication Date Title
NZ710575A (en) Pharmaceutical compositions for the treatment of diabetes mellitus
JP2008007519A5 (enExample)
JP2014533680A5 (enExample)
JP2011509252A5 (enExample)
AR047779A1 (es) Composiciones y metodos para tratar diabetes
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2013002244A (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
RU2013110003A (ru) Комбинация соединений для лечения или предотвращения кожных заболеваний
ZA202309366B (en) Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
JP2008545715A5 (enExample)
JP2020536121A5 (enExample)
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
JP7758655B2 (ja) 組合せ
CA2669853A1 (en) Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
JP2024534156A (ja) Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ
CO2023002829A2 (es) Formulación compuesta para tratamiento de diabetes mellitus tipo 2
FI3519050T3 (fi) Koostumuksia silmätautien hoitamiseksi
JP2011105610A5 (enExample)
MX2022011129A (es) Composicion farmaceutica para la prevencion o el tratamiento de la diabetes y de enfermedades metabolicas asociadas a la misma.

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed